🔴 Tron (TRX) Analysis: Record $121 Billion Monthly Volume Supports Bullish Case, $0.30 Key

Tron (TRX) is quietly building bullish momentum under the radar, with data revealing that the Tron network has hit new all-time highs in multiple key metrics–all while holding above the key support levels of 20-day and 50-day Exponential Moving Averages (EMAs).

🔸 On-Chain Fundamentals Point to Growing Tron Network Strength

Active addresses on the Tron network have surged, with the 50-day and 100-day moving averages of this metric both reaching their highest historical levels. This points to a deepening user base and growing interaction with the network, bullish indicators that typically precede price rallies.

Supporting this trend is the record-breaking $121.2 billion in monthly transfer volume, equivalent to over 490.3 billion TRX moved across the network. This indicates sustained transactional demand, further reinforcing investor confidence in the Tron ecosystem.

💬 $TRX Hits $121.2B Monthly Transfer Volume — New All-Time High“TRX reached a new ATH in total transfer volume, both in terms of TRX and USD value. Over the course of the month, a total of 490.3 billion TRX was transferred.” – By @JA\_MaartunFull post — CryptoQuant.

🔸 Technical Analysis: TRX Eyes $0.3265 Target and Beyond After $0.30 Break

Meanwhile, TRX is currently trading around $0.2705 and consolidating just above key Fibonacci levels, as per CoinMarketCap data. The Fib retracement tool, applied from the recent low of $0.2613 to the swing high of $0.3016, outlines a series of potential breakout targets:

1. 618 Fib Extension at $0.3265
2. 618 Extension at $0.3667
3. 618 Extension at $0.4069
4. 236 Extension peaking at $0.4318

If TRX maintains network momentum and price breaks above the psychological resistance at $0.30, the first Target is $0.3265 with $0.4069–$0.4318 standing as long-term targets. Further, failure to hold the $0.2687–550 s celovek$0.2613 support zone could open the door to further declines to $0.2613 and $0.2450.

#TRX #Tron
{spot}(TRXUSDT)